Benoit Callendret1, Heather B Eccleston1, William Satterfield2, Stefania Capone3, Antonella Folgori3, Riccardo Cortese3, Alfredo Nicosia3,4,5,6, Christopher M Walker1,7. 1. Center for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH. 2. Department of Veterinary Sciences, Michale E. Keeling Center for Comparative Medicine and Research, M.D. Anderson Cancer Center, Bastrop, TX. 3. ReiThera, Rome, Italy. 4. KEIRES, Basel, Switzerland. 5. CEINGE, Naples, Italy. 6. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy. 7. Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH.
Abstract
UNLABELLED: Exhaustion of antiviral CD8(+) T cells contributes to persistence of hepatitis C viral (HCV) infection. This immune response has proved difficult to restore by therapeutic vaccination, even when HCV replication is suppressed using antiviral regimens containing type I interferon. Because immunomodulatory effects of type I interferon may be a factor in poor T-cell priming, we undertook therapeutic vaccination in two chronically infected chimpanzees during treatment with a direct-acting antiviral (DAA) targeting the HCV NS5b polymerase protein. Immunization with genetic vaccines encoding the HCV NS3-NS5b nonstructural proteins during DAA treatment resulted in a multifunctional CD8(+) T-cell response. However, these antiviral CD8(+) T cells did not prevent persistent replication of DAA-resistant HCV variants that emerged during treatment. Most vaccine-induced CD8(+) T cells targeted class I epitopes that were not conserved in the circulating virus. Exhausted intrahepatic CD8(+) T-cell targeting-conserved epitopes did not expand after vaccination, with a notable exception. A sustained, multifunctional CD8(+) T-cell response against at least one intact class I epitope was detected in blood after vaccination. Persistence of HCV was not due to mutational escape of this epitope. Instead, failure to control HCV replication was likely caused by localized exhaustion in the liver, where CD8(+) T-cell expression of the inhibitory receptor programmed cell death 1 increased 25-fold compared with those in circulation. CONCLUSION: Treatment with a DAA during therapeutic vaccination provided transient control of HCV replication and a multifunctional T-cell response, primarily against nonconserved class I epitopes; exhaustion of liver-infiltrating CD8(+) T cells that target conserved epitopes may not be averted when DAA therapy fails prematurely due to emergence of resistant HCV variants.
UNLABELLED: Exhaustion of antiviral CD8(+) T cells contributes to persistence of hepatitis C viral (HCV) infection. This immune response has proved difficult to restore by therapeutic vaccination, even when HCV replication is suppressed using antiviral regimens containing type I interferon. Because immunomodulatory effects of type I interferon may be a factor in poor T-cell priming, we undertook therapeutic vaccination in two chronically infected chimpanzees during treatment with a direct-acting antiviral (DAA) targeting the HCV NS5b polymerase protein. Immunization with genetic vaccines encoding the HCV NS3-NS5b nonstructural proteins during DAA treatment resulted in a multifunctional CD8(+) T-cell response. However, these antiviral CD8(+) T cells did not prevent persistent replication of DAA-resistant HCV variants that emerged during treatment. Most vaccine-induced CD8(+) T cells targeted class I epitopes that were not conserved in the circulating virus. Exhausted intrahepatic CD8(+) T-cell targeting-conserved epitopes did not expand after vaccination, with a notable exception. A sustained, multifunctional CD8(+) T-cell response against at least one intact class I epitope was detected in blood after vaccination. Persistence of HCV was not due to mutational escape of this epitope. Instead, failure to control HCV replication was likely caused by localized exhaustion in the liver, where CD8(+) T-cell expression of the inhibitory receptor programmed cell death 1 increased 25-fold compared with those in circulation. CONCLUSION: Treatment with a DAA during therapeutic vaccination provided transient control of HCV replication and a multifunctional T-cell response, primarily against nonconserved class I epitopes; exhaustion of liver-infiltrating CD8(+) T cells that target conserved epitopes may not be averted when DAA therapy fails prematurely due to emergence of resistant HCV variants.
Authors: Adrian M Di Bisceglie; Ewa Janczweska-Kazek; François Habersetzer; Wlodzimierz Mazur; Carol Stanciu; Vicente Carreno; Coman Tanasescu; Robert Flisiak; Manuel Romero-Gomez; Alexander Fich; Vincent Bataille; Myew-Ling Toh; Marie Hennequi; Patricia Zerr; Géraldine Honnet; Geneviève Inchauspé; Delphine Agathon; Jean-Marc Limacher; Heiner Wedemeyer Journal: Gastroenterology Date: 2014-03-18 Impact factor: 22.682
Authors: Solomon Owusu Sekyere; Pothakamuri Venkata Suneetha; Anke Renate Maria Kraft; Shihong Zhang; Julia Dietz; Christoph Sarrazin; Michael Peter Manns; Verena Schlaphoff; Markus Cornberg; Heiner Wedemeyer Journal: J Hepatol Date: 2014-08-15 Impact factor: 25.083
Authors: Rachel H McMahan; Lucy Golden-Mason; Michael I Nishimura; Brian J McMahon; Michael Kemper; Todd M Allen; David R Gretch; Hugo R Rosen Journal: J Clin Invest Date: 2010-11-15 Impact factor: 14.808
Authors: Eric J Gowans; Stuart Roberts; Kathryn Jones; Irene Dinatale; Philippe A Latour; Brendan Chua; Emily M Y Eriksson; Ruth Chin; Shuo Li; Dominic M Wall; Rosemary L Sparrow; Jude Moloney; Maureen Loudovaris; Rosemary Ffrench; H Miles Prince; Derek Hart; Weng Zeng; Joseph Torresi; Lorena E Brown; David C Jackson Journal: J Hepatol Date: 2010-06-20 Impact factor: 25.083
Authors: Steven S Carroll; Steven Ludmerer; Larry Handt; Kenneth Koeplinger; Nanyan Rena Zhang; Donald Graham; Mary-Ellen Davies; Malcolm MacCoss; Daria Hazuda; David B Olsen Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191
Authors: Michael J Fuller; Benoit Callendret; Baogong Zhu; Gordon J Freeman; Dana L Hasselschwert; William Satterfield; Arlene H Sharpe; Lynn B Dustin; Charles M Rice; Arash Grakoui; Rafi Ahmed; Christopher M Walker Journal: Proc Natl Acad Sci U S A Date: 2013-08-26 Impact factor: 11.205
Authors: Krupa R Mysore; Rafik M Ghobrial; Sunil Kannanganat; Laurie J Minze; Edward A Graviss; Duc T Nguyen; Katherine K Perez; Xian C Li Journal: Am J Transplant Date: 2017-11-20 Impact factor: 8.086
Authors: Leo Swadling; John Halliday; Christabel Kelly; Anthony Brown; Stefania Capone; M Azim Ansari; David Bonsall; Rachel Richardson; Felicity Hartnell; Jane Collier; Virginia Ammendola; Mariarosaria Del Sorbo; Annette Von Delft; Cinzia Traboni; Adrian V S Hill; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Paul Klenerman; Antonella Folgori; Eleanor Barnes Journal: Vaccines (Basel) Date: 2016-08-02
Authors: Olga V Masalova; Ekaterina I Lesnova; Regina R Klimova; Ekaterina D Momotyuk; Vyacheslav V Kozlov; Alla M Ivanova; Olga V Payushina; Nina N Butorina; Natalia F Zakirova; Alexander N Narovlyansky; Alexander V Pronin; Alexander V Ivanov; Alla A Kushch Journal: Vaccines (Basel) Date: 2020-02-02